reports
Eris Lifesciences Ltd: 1 director
A director at Eris Lifesciences Ltd bought 203,000 shares at 630.000INR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Tushar Manudhane
MOSL : ERIS LIFESCIENCES: Enhanced efforts toward product launch-rela...
ERIS LIFESCIENCES: Enhanced efforts toward product launch-related activities (ERIS IN, Mkt Cap USD1.2b, CMP INR708, TP INR860, 21% Upside, Buy) Eris Lifesciences (ERIS) delivered better than expected 2QFY23 performance, led by superior traction in new launches and improved operating leverage. ERIS is notonly sustaining the momentum in its recently launched products, but it is also preparing itself for an aggressive pace of new introductions. We reiterate our earnings estimate for FY23/FY24 ...
- Tushar Manudhane
MOSL: ERIS LIFESCIENCES: Steady outperformance across major therapies
ERIS LIFESCIENCES: Steady outperformance across major therapies (ERIS IN, Mkt Cap USD1.2b, CMP INR695, TP INR850, 22% Upside, Buy) ERIS delivered an operationally better-than-expected 1QFY23 performance, led by outperforming the industry in Cardio-metabolic, CNS, Dermatology, and Women’s Health therapies. In addition to gaining market share in existing brands, it is on track for introductions across major therapies over the next 12-15 months. We reduce our FY23/FY24 EPS estimate by 8%/2%, f...
- Dave Nicoski
- Ross LaDuke
Vermilion Int'l Compass: Global Equity Strategy
EM Pullback Opportunity Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point, concerns surrounding the Wuhan coronavirus have led to some market setbacks and deterioration in market indicators, however they have not resulted in breakdowns. This is true even for areas of the market most-directly affected, including China (MSCI China) and emerging markets (MSCI EM). For these reasons and, as long as ther...
QQ. QINETIQ GROUP PLC
VOLV B VOLVO AB CLASS B
GTT GAZTRANSPORT & TECHNIGAZ SA
LONN LONZA GROUP AG
CAE. CAE INC.
DEMANT DEMANT A/S
SVW SEVEN GROUP HOLDINGS LIMITED
DRREDDY DR. REDDY'S LABORATORIES LTD.
COTN COMET HOLDING AG
GN GN STORE NORD A/S
BAYN BAYER AG
AMP AMPLIFON S.P.A.
IMPN IMPLENIA AG
KLR KELLER GROUP PLC
ARCAD ARCADIS NV
SRT SARTORIUS AG
600079 HUMANWELL HEALTHCARE (GROUP) CO. LTD. CLASS A
RHC RAMSAY HEALTH CARE LIMITED
4506 SUMITOMO DAINIPPON PHARMA CO. LTD.
4536 SANTEN PHARMACEUTICAL CO. LTD.
SFZN SIEGFRIED HOLDING AG
078160 MEDIPOST
TORNTPHARM TORRENT PHARMACEUTICALS LTD
SPARC SUN PHARMA ADVANCED RESEARCH
600998 JOINTOWN PHARMACEUTICAL GROUP CO. LTD. CLASS A
GRANULES GRANULES INDIA
ZEH ZEHNDER GROUP AG CLASS A
DIM SARTORIUS STEDIM BIOTECH SA
4552 JCR PHARMACEUTICALS CO. LTD.
BSS BIESSE S.P.A.
ASHOKLEY ASHOK LEYLAND LIMITED
300122 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO. LTD. CLASS A
185750 CHONG KUN DANG PHARMACEUTICAL
IDIA IDORSIA LTD.
ERIS ERIS LIFESCIENCES
BIM BIOMERIEUX SA
2269 WUXI BIOLOGICS (CAYMAN) INC.
GULF GULF ENERGY DEVELOPMENT PUBLIC COMPANY LIMITED
EPI A EPIROC AB CLASS A
KBX KNORR-BREMSE AG
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.